Free Trial

Arvinas (ARVN) Competitors

Arvinas logo
$7.58 -0.16 (-2.00%)
As of 12:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ARVN vs. IBRX, DNLI, OCUL, BLTE, AGIO, IRON, ARQT, ANIP, HRMY, and IDYA

Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include ImmunityBio (IBRX), Denali Therapeutics (DNLI), Ocular Therapeutix (OCUL), Belite Bio (BLTE), Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), ANI Pharmaceuticals (ANIP), Harmony Biosciences (HRMY), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry.

Arvinas vs. Its Competitors

Arvinas (NASDAQ:ARVN) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Arvinas has higher revenue and earnings than ImmunityBio. Arvinas is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$263.40M2.11-$198.90M-$1.01-7.51
ImmunityBio$14.74M174.11-$413.56M-$0.48-5.66

Arvinas has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.

Arvinas presently has a consensus target price of $19.76, suggesting a potential upside of 160.56%. ImmunityBio has a consensus target price of $10.75, suggesting a potential upside of 295.95%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Arvinas.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arvinas
0 Sell rating(s)
10 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.55
ImmunityBio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 4.7% of Arvinas shares are owned by insiders. Comparatively, 76.8% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arvinas has a net margin of -19.47% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat Arvinas' return on equity.

Company Net Margins Return on Equity Return on Assets
Arvinas-19.47% -12.01% -6.97%
ImmunityBio -648.57%N/A -113.86%

In the previous week, ImmunityBio had 5 more articles in the media than Arvinas. MarketBeat recorded 7 mentions for ImmunityBio and 2 mentions for Arvinas. Arvinas' average media sentiment score of 1.47 beat ImmunityBio's score of 0.50 indicating that Arvinas is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arvinas
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ImmunityBio
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ImmunityBio beats Arvinas on 9 of the 17 factors compared between the two stocks.

Get Arvinas News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARVN vs. The Competition

MetricArvinasMED IndustryMedical SectorNASDAQ Exchange
Market Cap$555.79M$3.10B$5.72B$10.28B
Dividend YieldN/A2.32%5.73%4.60%
P/E Ratio-7.5021.4375.3226.21
Price / Sales2.11247.02457.8689.68
Price / CashN/A44.4425.8129.91
Price / Book0.939.5813.296.27
Net Income-$198.90M-$53.20M$3.29B$270.67M
7 Day Performance-4.47%-0.04%0.71%2.72%
1 Month Performance6.98%3.80%4.57%5.87%
1 Year Performance-69.72%9.02%73.81%25.85%

Arvinas Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARVN
Arvinas
2.9834 of 5 stars
$7.59
-2.0%
$19.76
+160.6%
-69.1%$555.79M$263.40M-7.50420Positive News
IBRX
ImmunityBio
2.5039 of 5 stars
$2.41
+0.4%
$10.75
+346.1%
-27.4%$2.28B$56.60M-5.02590
DNLI
Denali Therapeutics
4.3653 of 5 stars
$15.50
+0.5%
$33.62
+116.9%
-53.9%$2.27B$330.53M-5.54430Positive News
OCUL
Ocular Therapeutix
4.0219 of 5 stars
$12.71
-6.5%
$17.20
+35.3%
+42.3%$2.21B$63.72M-9.93230News Coverage
Positive News
Analyst Forecast
BLTE
Belite Bio
2.578 of 5 stars
$67.51
+2.7%
$96.67
+43.2%
+42.3%$2.15BN/A-43.5510Analyst Forecast
AGIO
Agios Pharmaceuticals
4.3185 of 5 stars
$36.41
+1.1%
$56.00
+53.8%
-21.2%$2.12B$36.50M3.31390
IRON
Disc Medicine
3.2282 of 5 stars
$61.91
+1.9%
$98.30
+58.8%
+25.2%$2.11BN/A-13.8530Positive News
ARQT
Arcutis Biotherapeutics
2.4501 of 5 stars
$17.33
+1.0%
$19.80
+14.3%
+62.2%$2.08B$196.54M-23.11150
ANIP
ANI Pharmaceuticals
3.9418 of 5 stars
$95.20
-0.2%
$88.25
-7.3%
+67.0%$2.07B$614.38M-123.63600
HRMY
Harmony Biosciences
4.6065 of 5 stars
$35.83
-0.4%
$51.00
+42.3%
-16.8%$2.06B$714.73M11.56200Positive News
IDYA
IDEAYA Biosciences
3.9823 of 5 stars
$23.39
-13.9%
$45.77
+95.7%
-34.3%$2.05B$7M-6.1780Analyst Forecast
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ARVN) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners